Live varicella vaccine: prevention of nosocomial infection and protection of high risk infants from varicella infection.
For prevention of nosocomial infection, 25 infants including high risk patients received an emergency injection of live varicella vaccine. Three patients developed a rash within 5 days after vaccination, but their symptoms were mild. The other 22 showed no clinical symptoms and gave an immune response. Twenty-two patients receiving immunosuppressive therapy were vaccinated and 20 of them showed a positive response in the varicella skin test. Of 14 vaccinated patients with malignancies, 2 giving a positive skin test, later showed clinical varicella, but their symptoms were not severe. One case with ALL was immunized safely under very poor conditions during the first induction therapy. No complications were observed in any patients.
D002644:Chickenpox / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000517:prevention & control*; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000276:immunology*; D008297:Male; D009369:Neoplasms / Q000276:immunology*; D009404:Nephrotic Syndrome / Q000276:immunology*; D012306:Risk; D012882:Skin Tests; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology*
D014613:Vaccines, Attenuated; D014765:Viral Vaccines